< CE News
Reviewing Clinical Therapy Advances and Management of Amyotrophic Lateral Sclerosis
Thu, Feb 28, 2019 10:58 PM UTC
Date: Wednesday, May 1, 2019
Location: Wynn and Encore Hotels
3131 S Las Vegas Boulevard
Las Vegas, Nevada 89109
Time: 12:00 pm – 1:30 pm
*Lunch will be available
An estimated 20,000 people in the United States are living with amyotrophic lateral sclerosis (ALS). ALS is a progressive disease in which the motor neurons eventually die. Mortality is usually the result of respiratory failure. Although most patients with ALS die within 3 to 5 years after symptoms first appear, about 20% of patients with ALS will live 5 years, 10% will live 10 years, and about 5% will live 20 years or more. Currently, there is no cure for ALS; however, in the last decade, advances have been made that are changing the medical treatment landscape of ALS. As new therapies enter into ALS care, a multitude of health care professionals will need to understand more about the disease, therapies, and the nuances of these therapies within ALS care. Ultimately, pharmacists must be part of the health care team to make decisions on medications and therapies that will improve the patient’s quality of life and slow the disease progression, while helping to navigate access to appropriate therapies and manage costs.
- Examine the pathophysiology and degenerative effects of amyotrophic lateral sclerosis (ALS)
- Explore current therapies available for pharmacologic intervention in ALS
- Distinguish the direct and indirect costs of ALS and approaches to cost management
- Identify methods to navigate access to appropriate ALS therapies
Sarah Dehoney, PharmD, BCPS
Neurology Clinic Pharmacist
University of Utah Department of Neurology
Salt Lake City, Utah
Micaila Ruiz, PharmD
This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America, Inc.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity 0290-0000-19-054-L01-P. The activity is available for CE credit for May 1, 2019.
All participants who attended the live symposium need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Detailed instructions on obtaining credit will be provided at the session. Credit must be requested no later than July 1, 2019.